Analysts Are Bullish on These Healthcare Stocks: Dexcom (DXCM), Medline (MDLN)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dexcom (DXCM – Research Report), Medline (MDLN – Research Report) and Amylyx Pharmaceuticals Inc (AMLX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dexcom (DXCM)
In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Dexcom, with a price target of $85.00. The company’s shares closed last Friday at $68.10, close to its 52-week low of $62.34.
According to TipRanks.com, Thibault is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $86.94 average price target, implying a 24.7% upside from current levels. In a report issued on February 27, TipRanks – xAI also upgraded the stock to Buy with a $83.00 price target.
See today’s best-performing stocks on TipRanks >>
Medline (MDLN)
In a report released today, David Larsen from BTIG reiterated a Buy rating on Medline, with a price target of $55.00. The company’s shares closed last Friday at $43.83.
According to TipRanks.com, Larsen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medline with a $52.04 average price target, which is a 21.0% upside from current levels. In a report issued on February 27, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $56.00 price target.
Amylyx Pharmaceuticals Inc (AMLX)
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Amylyx Pharmaceuticals Inc. The company’s shares closed last Friday at $13.85.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
Currently, the analyst consensus on Amylyx Pharmaceuticals Inc is a Strong Buy with an average price target of $23.14, implying a 67.4% upside from current levels. In a report issued on March 3, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $21.00 price target.
